Medtronic PLC said Wednesday it acquired Stimgenics LLC, a privately held company that has developed a spinal cord stimulation therapy to treat patients with chronic pain.
Dublin-based Medtronic said the transaction is expected to be neutral to fiscal 2020 earnings per share and meet its long-term financial metrics for acquisitions. Additional terms of the transaction weren’t disclosed.
Randomized control trial results evaluating the Bloomington, Ill.-based Stimgenics’ Differential Target Multiplexed (DTM) Spinal Cord Stimulation therapy versus conventional SCS will be presented at the North American Neuromodulation Society Annual Meeting on Jan. 23-26 in Las Vegas.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.